IDentif.AI-Optimized COVID-19 Drug Combinations for XBB Variant

31.8 KB Excel file contains results from an AI platform (IDentif.AI) used to optimize drug combinations for COVID-19 treatment. The data, authored by Peter Wang and last updated in June 2026, details combinations that resurrect the potency of the antibody sotrovimab against the XBB variant. The study identified synergistic pairs that reduced the in vitro EC50 of sotrovimab by up to 7-fold.

Use Cases

• Validate AI-predicted drug synergy based on reported EC50 fold-reduction.
• Model therapeutic efficacy against SARS-CoV-2 variants based on combination data.
• Prioritize candidate drug pairs for in vitro testing against emerging variants.
• Study platform strategies for repurposing failed or existing therapeutics.

Strengths

• Specific EC50 fold-reduction (up to 7-fold) is quantified.
• Data is associated with a named AI optimization platform (IDentif.AI).
• Clear focus on a specific therapeutic (sotrovimab) and variant (XBB).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 31.8 KB file size suggests a very limited data scope.

Provenance

Source

figshare, author Peter Wang.

Collection Method

Likely contains results from an AI-derived drug combination optimization platform (IDentif.AI) applied to in vitro testing.

Freshness

Last updated 2026-06-02 05:26:40; freshness should be verified.